EGFR and non-small cell lung carcinoma: The third-generation inhibitor Osimertinib also acts on this mutation, bypassing the resistance mechanism, and is now a pillar in the treatment of EGFR-mutated NSCLC as a first-line metastatic treatment [113,114].